GLP-1s & Weight Loss
Retatrutide
← Back to Library
Human trial protocol FDA safety flag Protocol not independently verified Incretin Metabolic Thermogenic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 15, 20, 30, 50, 60 mg
Dosing window: Morning
Receptor / target: GLP-1; GIP; Glucagon
Properties: Incretin
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.0mg once weekly | Initiation phase. |
| Weeks 5-8 | 4.0mg once weekly | Therapeutic escalation. |
| Weeks 9-12 | 6.0mg once weekly | Monitor heart rate carefully at this stage. |
| Weeks 13-16 | 8.0mg once weekly | Advanced plateau breaker. |
| Weeks 17-20 | 10.0mg once weekly | Pre-maximum dose. |
| Weeks 21+ | 12.0mg once weekly | Maximum studied dose. Highly advanced subjects only. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Conservative Start
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.5mg to 1.0mg once weekly | Significantly lowers cardiovascular stress and initial heart rate spikes. |
| Weeks 5-8 | 2.0mg once weekly | Moves into standard initiation phase. |
| Weeks 9-12 | 3.0mg once weekly | Titrating by 1mg instead of 2mg prevents extreme hyperesthesia (skin sensitivity). |
| Weeks 13+ | 4.0mg once weekly | Continue titrating by 1.0mg as needed based on tolerance. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1; GIP; Glucagon); route Subcutaneous; timing Morning. Trial exposure can explain a dose range; it does not validate every goal, stack, or long-term cycle. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Clinical trial regimen(s): Phase 2 obesity trial: once-weekly SC retatrutide 1 mg, 4 mg, 8 mg, or 12 mg for 48 weeks with specified lower initial-dose arms.
Independent safety notes: FDA states retatrutide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
Regulatory status: investigational not FDA approved
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Personal or family history of thyroid C-cell tumors.
- Pre-existing cardiac arrhythmias or tachycardia: glucagon receptor activation directly elevates heart rate.
- Uncontrolled hypertension: cardiovascular stress from glucagon agonism may exacerbate elevated blood pressure.
- History of acute pancreatitis.
- Severe gastroparesis or clinically significant delayed gastric emptying.
- Type 1 diabetes mellitus.
- Diabetic ketoacidosis.
- Pregnancy: insufficient safety data; discontinue well in advance of planned conception.
- Breastfeeding: insufficient safety data.
- Known hypersensitivity or anaphylaxis to retatrutide or any formulation excipient.
- Concurrent use with any other GLP-1, GIP, or glucagon receptor agonist: direct pharmacological conflict and additive cardiovascular risk.
- History of suicidal ideation or prior suicide attempts: monitor closely.
- Planned general anesthesia or elective surgery: delayed gastric emptying raises pulmonary aspiration risk; follow pre-operative fasting protocols.
- Severe hepatic impairment: glucagon receptor activity directly affects hepatic metabolism; limited safety data.
- End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution.
- Pediatric use: safety and efficacy not established.
- Use in subjects with active cardiovascular disease without cardiac monitoring: resting heart rate elevations of 8-10 BPM or more have been reported in clinical trials.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Elevated resting heart rate (tachycardia): driven by glucagon receptor agonism; the most pharmacologically unique side effect of this compound vs. other incretins.
- Skin hyperesthesia: unusual sensitivity or hypersensitivity to touch, particularly on the arms, torso, and thighs; dose-dependent and most prominent at higher doses.
- Nausea: common during dose escalation phases.
- Vomiting.
- Diarrhea.
- Constipation.
- Abdominal pain and cramping.
- Decreased appetite and dysgeusia (altered taste).
- Gastroparesis: delayed gastric emptying; may persist even with pre-operative fasting.
- Fatigue and lethargy: particularly pronounced during early high-dose phases.
- Headache.
- Dizziness.
- Elevated blood pressure: secondary to heart rate increases and sympathomimetic effects of glucagon receptor activation.
- Hypoglycemia: risk elevated when combined with insulin or sulfonylureas.
- Acute pancreatitis: documented in incretin class compounds; causal relationship under investigation.
- Acute kidney injury: primarily mediated by dehydration from GI side effects.
- Cholelithiasis (gallstones): risk increases with rapid weight loss.
- Thyroid C-cell tumor risk: confirmed in rodent models; human risk not yet established; monitor for neck mass, hoarseness, or dysphagia.
- Alopecia (hair loss): reported across incretin class; likely secondary to rapid caloric restriction.
- Injection site reactions: redness, itching, bruising at administration site.
- Anaphylaxis and angioedema: rare but documented across the incretin class.
- Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
- Rapid weight regain upon discontinuation: expected without lifestyle intervention; metabolic rate normalization post-cessation accelerates rebound.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://pubmed.ncbi.nlm.nih.gov/37366315/
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- PubMed search: Retatrutide
- PubMed trial search: retatrutide obesity phase 2